Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters'' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters'' option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share. All shares of common stock were offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $172.5 million. J.P. Morgan, Cowen and Piper Sandler acted as the joint book-running managers for the offering. Wedbush PacGrow acted as the lead manager for the offering. The securities were offered by Day One pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC).
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters'' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters'' option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share. All shares of common stock were offered by Day One. The gross proceeds to Day One from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $172.5 million. J.P. Morgan, Cowen and Piper Sandler acted as the joint book-running managers for the offering. Wedbush PacGrow acted as the lead manager for the offering. The securities were offered by Day One pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC).